Review rules out rosuvastatin use
Fluvastatin and rosuvastatin should not be used in routine management of patients, an influential review journal concludes.The Drug and Therapeutics Bulletin reviewed previous research on statins and concluded that fluvastatin and rosuvastatin were overpriced for their benefits. It said simvastatin was similarly effective at lower cost.Drug switching was also backed by the review, which concluded many patients currently taking atorvastatin could be switched to simvastatin.The DTB reported: 'Atorvastatin should be reserved for second-line treatment or for patients who are intolerant of simvastatin. 'There is very limited clinical trial data for fluvastatin or rosuvastatin. These are much more expensive than simvastatin and we can see no reason for using them in routine management.'But some GPs argue that because rosuvastatin is a relatively new drug there has not been time to gauge its impact.Dr George Kassianos, a GP in Bracknell, Berkshire, and member of the Primary Care Cardiovascular Society, said the picture may change when imminent research concerning rosuvastatin is published.'The results I have seen so far for rosuvastatin are excellent. Before we make a conclusion we should wait for this new study.'Dr John Pittard, a GP in Staines, Middlesex, and CHD lead at North Surrey PCT, said: 'Rosuvastatin is a new drug and it is a mistake to say we should not be using it just because of that.'